Anti–CTLA-4 therapy requires an Fc domain for efficacy

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate...

Full description

Saved in:
Bibliographic Details
Published in:Proc Natl Acad Sci U S A
Main Authors: Ingram, Jessica R., Blomberg, Olga S., Rashidian, Mohammad, Ali, Lestat, Garforth, Scott, Fedorov, Elena, Fedorov, Alexander A., Bonanno, Jeffrey B., Le Gall, Camille, Crowley, Stephanie, Espinosa, Camilo, Biary, Tamara, Keliher, Edmund J., Weissleder, Ralph, Almo, Steven C., Dougan, Stephanie K., Ploegh, Hidde L., Dougan, Michael
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2018
Subjects:
Biological Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5899492/
https://ncbi.nlm.nih.gov/pubmed/29581255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1801524115
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items